Stoke Therapeutics Q3 2024 Earnings Report
Key Takeaways
Stoke Therapeutics reported revenue of $4.9 million and a net loss of $26.4 million for the third quarter of 2024. The company had $269.2 million in cash, cash equivalents, and marketable securities as of September 30, 2024.
Company plans to provide seizure as well as cognition and behavior data from all patients treated with initial 70mg doses followed by 45mg maintenance dosing in studies of zorevunersen by year-end.
Discussions with FDA and global regulatory agencies related to a single global Phase 3 study of zorevunersen continue to progress; Company to provide an update by year-end.
FDA has removed the Partial Clinical Hold on zorevunersen.
As of September 30, 2024, Company had $269.2 million in cash, cash equivalents, and marketable securities.
Stoke Therapeutics
Stoke Therapeutics
Forward Guidance
The Company plans to provide an update on Phase 3 registrational plans for zorevunersen by year-end.